216 related articles for article (PubMed ID: 31839441)
1. Targeting CDK2 in cancer: challenges and opportunities for therapy.
Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S
Drug Discov Today; 2020 Feb; 25(2):406-413. PubMed ID: 31839441
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
Tadesse S; Caldon EC; Tilley W; Wang S
J Med Chem; 2019 May; 62(9):4233-4251. PubMed ID: 30543440
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
Chohan TA; Qian H; Pan Y; Chen JZ
Curr Med Chem; 2015; 22(2):237-63. PubMed ID: 25386824
[TBL] [Abstract][Full Text] [Related]
4. Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.
Ling H; Samarasinghe S; Kulasiri D
Biosystems; 2013 Feb; 111(2):71-82. PubMed ID: 23254306
[TBL] [Abstract][Full Text] [Related]
5. To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response.
Liu Q; Gao J; Zhao C; Guo Y; Wang S; Shen F; Xing X; Luo Y
DNA Repair (Amst); 2020 Jan; 85():102702. PubMed ID: 31731257
[TBL] [Abstract][Full Text] [Related]
6. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
7. Development of CDK2 and CDK5 Dual Degrader TMX-2172.
Teng M; Jiang J; He Z; Kwiatkowski NP; Donovan KA; Mills CE; Victor C; Hatcher JM; Fischer ES; Sorger PK; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2020 Aug; 59(33):13865-13870. PubMed ID: 32415712
[TBL] [Abstract][Full Text] [Related]
8. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.
Hu S; Danilov AV; Godek K; Orr B; Tafe LJ; Rodriguez-Canales J; Behrens C; Mino B; Moran CA; Memoli VA; Mustachio LM; Galimberti F; Ravi S; DeCastro A; Lu Y; Sekula D; Andrew AS; Wistuba II; Freemantle S; Compton DA; Dmitrovsky E
Cancer Res; 2015 May; 75(10):2029-38. PubMed ID: 25808870
[TBL] [Abstract][Full Text] [Related]
9. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
10. A model for CDK2 in maintaining genomic stability.
Zhu Y
Cell Cycle; 2004 Nov; 3(11):1358-62. PubMed ID: 15492512
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
Liu JJ; Daniewski I; Ding Q; Higgins B; Ju G; Kolinsky K; Konzelmann F; Lukacs C; Pizzolato G; Rossman P; Swain A; Thakkar K; Wei CC; Miklowski D; Yang H; Yin X; Wovkulich PM
Bioorg Med Chem Lett; 2010 Oct; 20(20):5984-7. PubMed ID: 20832307
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex.
Zhang G; Ma F; Li L; Li J; Li P; Zeng S; Sun H; Li E
Biochem Pharmacol; 2019 May; 163():133-141. PubMed ID: 30772267
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
15. A patent review of anticancer CDK2 inhibitors (2017-present).
Said MA; Abdelrahman MA; Abourehab MAS; Fares M; Eldehna WM
Expert Opin Ther Pat; 2022 Aug; 32(8):885-898. PubMed ID: 35583393
[TBL] [Abstract][Full Text] [Related]
16. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
Elbæk CR; Petrosius V; Sørensen CS
Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
[TBL] [Abstract][Full Text] [Related]
17. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review.
Volkart PA; Bitencourt-Ferreira G; Souto AA; de Azevedo WF
Curr Drug Targets; 2019; 20(7):716-726. PubMed ID: 30516105
[TBL] [Abstract][Full Text] [Related]
19. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
